In immunodeficient SCID mice lacking T and B cells, VIP antagonist alone or in combination with anti-PD-1 reduced CT26 tumor growth, which was associated with increases in M1/M2 macrophage ratio and macrophage phagocytosis of CT26 in the tumors. Here, DDX53 is linked to neoplasm.